Next Phase in Effective Cost Control in Health Care

In this Viewpoint, Ezekiel Emanuel and colleagues make policy recommendations to control continued growth in health care spending, including national US drug price negotiation, linking benchmarks for cost growth to economic growth and population aging, expansion of alternative payment models to priv...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2019-03, Vol.321 (12), p.1151-1152
Main Authors: Glickman, Aaron, DiMagno, Sarah S. P, Emanuel, Ezekiel J
Format: Article
Language:English
Subjects:
Aging
Benchmarks
Business competition
Economic development
Economic growth
Economic models
Federal legislation
Health care
Health care expenditures
Legislation
Prescription drugs
Pricing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3
cites cdi_FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3
container_end_page 1152
container_issue 12
container_start_page 1151
container_title JAMA : the journal of the American Medical Association
container_volume 321
creator Glickman, Aaron
DiMagno, Sarah S. P
Emanuel, Ezekiel J
description In this Viewpoint, Ezekiel Emanuel and colleagues make policy recommendations to control continued growth in health care spending, including national US drug price negotiation, linking benchmarks for cost growth to economic growth and population aging, expansion of alternative payment models to private health care markets, and federal antitrust legislation to address market consolidation that reduces competition and increases prices.
doi_str_mv 10.1001/jama.2019.1608
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2188980137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2728102</ama_id><sourcerecordid>2213147077</sourcerecordid><originalsourceid>FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3</originalsourceid><addsrcrecordid>eNpdkDtPwzAURi0EoqWwMjCgSCwsCdeP2M6IokKRKmCA2XJiR02VR7ETBP-eWC0MeLCH79yHD0KXGBIMgO-2utUJAZwlmIM8QnOcUhnTNJPHaA6QyVgwyWbozPstTAdTcYpmFCRjQOQc0Wf7NUSvG-1tVHfRsqpsOdSfNsp7P0xXN7i-CcnK6mbYRLl29hydVLrx9uLwLtD7w_ItX8Xrl8en_H4da8rIEDMoqsJwzUTBhcyISY2ASlPMBEsF4UbyNNWi5MZkhqTcGlNkXEIhKCmssXSBbvd9d67_GK0fVFv70jaN7mw_ekWwlJkMX5rQm3_oth9dN22nCMFhJIhAJXuqdL33zlZq5-pWu2-FQQWdKuhUQacKOqeC60PbsWit-cN__U3A1R4Idb8pEURiIPQHSnF2GQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2213147077</pqid></control><display><type>article</type><title>Next Phase in Effective Cost Control in Health Care</title><source>American Medical Association (JAMA) - Bibliosan 2024</source><creator>Glickman, Aaron ; DiMagno, Sarah S. P ; Emanuel, Ezekiel J</creator><creatorcontrib>Glickman, Aaron ; DiMagno, Sarah S. P ; Emanuel, Ezekiel J</creatorcontrib><description>In this Viewpoint, Ezekiel Emanuel and colleagues make policy recommendations to control continued growth in health care spending, including national US drug price negotiation, linking benchmarks for cost growth to economic growth and population aging, expansion of alternative payment models to private health care markets, and federal antitrust legislation to address market consolidation that reduces competition and increases prices.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2019.1608</identifier><identifier>PMID: 30844028</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Aging ; Benchmarks ; Business competition ; Economic development ; Economic growth ; Economic models ; Federal legislation ; Health care ; Health care expenditures ; Legislation ; Prescription drugs ; Pricing</subject><ispartof>JAMA : the journal of the American Medical Association, 2019-03, Vol.321 (12), p.1151-1152</ispartof><rights>Copyright American Medical Association Mar 26, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3</citedby><cites>FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30844028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glickman, Aaron</creatorcontrib><creatorcontrib>DiMagno, Sarah S. P</creatorcontrib><creatorcontrib>Emanuel, Ezekiel J</creatorcontrib><title>Next Phase in Effective Cost Control in Health Care</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>In this Viewpoint, Ezekiel Emanuel and colleagues make policy recommendations to control continued growth in health care spending, including national US drug price negotiation, linking benchmarks for cost growth to economic growth and population aging, expansion of alternative payment models to private health care markets, and federal antitrust legislation to address market consolidation that reduces competition and increases prices.</description><subject>Aging</subject><subject>Benchmarks</subject><subject>Business competition</subject><subject>Economic development</subject><subject>Economic growth</subject><subject>Economic models</subject><subject>Federal legislation</subject><subject>Health care</subject><subject>Health care expenditures</subject><subject>Legislation</subject><subject>Prescription drugs</subject><subject>Pricing</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkDtPwzAURi0EoqWwMjCgSCwsCdeP2M6IokKRKmCA2XJiR02VR7ETBP-eWC0MeLCH79yHD0KXGBIMgO-2utUJAZwlmIM8QnOcUhnTNJPHaA6QyVgwyWbozPstTAdTcYpmFCRjQOQc0Wf7NUSvG-1tVHfRsqpsOdSfNsp7P0xXN7i-CcnK6mbYRLl29hydVLrx9uLwLtD7w_ItX8Xrl8en_H4da8rIEDMoqsJwzUTBhcyISY2ASlPMBEsF4UbyNNWi5MZkhqTcGlNkXEIhKCmssXSBbvd9d67_GK0fVFv70jaN7mw_ekWwlJkMX5rQm3_oth9dN22nCMFhJIhAJXuqdL33zlZq5-pWu2-FQQWdKuhUQacKOqeC60PbsWit-cN__U3A1R4Idb8pEURiIPQHSnF2GQ</recordid><startdate>20190326</startdate><enddate>20190326</enddate><creator>Glickman, Aaron</creator><creator>DiMagno, Sarah S. P</creator><creator>Emanuel, Ezekiel J</creator><general>American Medical Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20190326</creationdate><title>Next Phase in Effective Cost Control in Health Care</title><author>Glickman, Aaron ; DiMagno, Sarah S. P ; Emanuel, Ezekiel J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aging</topic><topic>Benchmarks</topic><topic>Business competition</topic><topic>Economic development</topic><topic>Economic growth</topic><topic>Economic models</topic><topic>Federal legislation</topic><topic>Health care</topic><topic>Health care expenditures</topic><topic>Legislation</topic><topic>Prescription drugs</topic><topic>Pricing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glickman, Aaron</creatorcontrib><creatorcontrib>DiMagno, Sarah S. P</creatorcontrib><creatorcontrib>Emanuel, Ezekiel J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glickman, Aaron</au><au>DiMagno, Sarah S. P</au><au>Emanuel, Ezekiel J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Next Phase in Effective Cost Control in Health Care</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2019-03-26</date><risdate>2019</risdate><volume>321</volume><issue>12</issue><spage>1151</spage><epage>1152</epage><pages>1151-1152</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>In this Viewpoint, Ezekiel Emanuel and colleagues make policy recommendations to control continued growth in health care spending, including national US drug price negotiation, linking benchmarks for cost growth to economic growth and population aging, expansion of alternative payment models to private health care markets, and federal antitrust legislation to address market consolidation that reduces competition and increases prices.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>30844028</pmid><doi>10.1001/jama.2019.1608</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0098-7484
ispartof JAMA : the journal of the American Medical Association, 2019-03, Vol.321 (12), p.1151-1152
issn 0098-7484
1538-3598
language eng
recordid cdi_proquest_miscellaneous_2188980137
source American Medical Association (JAMA) - Bibliosan 2024
subjects Aging
Benchmarks
Business competition
Economic development
Economic growth
Economic models
Federal legislation
Health care
Health care expenditures
Legislation
Prescription drugs
Pricing
title Next Phase in Effective Cost Control in Health Care
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T23%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Next%20Phase%20in%20Effective%20Cost%20Control%20in%20Health%20Care&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Glickman,%20Aaron&rft.date=2019-03-26&rft.volume=321&rft.issue=12&rft.spage=1151&rft.epage=1152&rft.pages=1151-1152&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2019.1608&rft_dat=%3Cproquest_cross%3E2213147077%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a342t-40bfbd6a47b67892d5d70fa314745726d8655a7c6dd9d256eddb9680b732bede3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2213147077&rft_id=info:pmid/30844028&rfr_iscdi=true